Efficacy of interleukin-1 blockade in Schnitzler’s syndrome without detectable monoclonal gammopathy: a case-based review

Riccardo Bixio1 · Maurizio Rossini1 · Alessandro Giollo1

Received: 20 September 2020 / Revised: 1 November 2020 / Accepted: 5 November 2020 / Published online: 11 November 2020
© The Author(s) 2020

Abstract
Schnitzler’s syndrome (SchS) is a rare autoinflammatory disorder characterized by urticarial rash and monoclonal gammopathy which is currently regarded as IL-1 mediated disease. We present the case of a 21-year-old woman presenting with urticarial rash, arthralgias, and elevated inflammatory markers. She has been suffering these symptoms for 2 years and was treated with antihistamines, omalizumab, steroids, and non-steroidal anti-inflammatory drugs (NSAIDs) without success. After an extensive diagnostic workout, we suspected SchS even without monoclonal gammopathy, and started Anakinra 100 mg daily with a dramatic response and achieving complete remission after 48 h of the beginning of the treatment, so we decided to confirm SchS diagnosis. We performed a search of the literature and found seven more cases of patients diagnosed with SchS without monoclonal gammopathy at the presentation. Five were treated with IL-1 blocking therapies and all achieved remission. We, therefore, prompt the possible role of IL-1 blockade therapy remission as support in diagnosing SchS without monoclonal gammopathy.

Keywords Anakinra · Canakinumab · IL-1 blockade · Monoclonal gammopathy · Paraprotein · Schnitzler’s syndrome

Introduction
Schnitzler’s syndrome (SchS) is a rare autoinflammatory disease described by L. Schnitzler in 1972 [1] characterized by urticarial rash and monoclonal gammopathy, usually Immunoglobulin (Ig) M or, rarely, IgG, associated with fever, joints and bones pain, enlarged lymph nodes, leukocytosis, and systemic inflammation (usually erythrosedimentation rate (ESR) and C-reactive protein (CRP) elevation) [2]. Long-term complication includes the development of lymphoproliferative diseases and amyloidosis. Two different diagnostic criteria (Lipsker’s and Strasbourg) have been developed and validated in real-life patients both with high sensitivity and specificity [3].

SchS diagnosis is challenging due to the rarity of the disease, and diagnostic workout usually needs to rule out many inflammatory, allergic, genetic, infectious, and neoplastic diseases. Adult-onset Still’s disease (AOSD), systemic lupus erythematosus (SLE), anti-neutrophil cytoplasm associated-vasculitis (AAV), periodic febrile syndromes such as cryopyrin-associated and tumor-necrosis factor-associated periodic syndromes (CAPS; TRAPS), cryoglobulinemia, Sweet’s disease, and lymphoma are the main alternative diagnosis [2].

The pathogenesis of the SchS is still debated but is generally accepted that SchS patients present a hyperactivation of the inflammasome. A recent study showed augmented neutrophils interleukin-1 receptor antagonist and interleukin-1 beta (IL-1 β) mRNA expression during active disease and a hyperresponsivity to LPS stimulation in SchS patients’ peripheral blood mononuclear cells, producing far more IL-1β and interleukin-6 (IL-6) than normal controls. This is consistent with the previous findings of augmented IL-1β and IL-6 serum levels in SchS patients, with higher levels correlating with more active disease [2, 4].

A great variety of treatments have been proposed for SchS, encompassing colchicine, dapsone, steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), thalidomide, TNF-blocking agents (anti-TNF), antihistamines, intravenous immunoglobulins, plasma exchange, methotrexate, azathioprine, pefloxacin, cyclophosphamide, tocilizumab, rituximab, and others, including traditional Chinese medicine [5, 6].

---
1 Rheumatology Section, Department of Medicine, University of Verona, Policlinico G.B. Rossi, Piazzale L.A. Scuro 10, 37134 Verona, Italy
Coherently with the pathogenetic hypothesis, IL-1 blockade is currently regarded as the most effective therapy in SchS: both anakinra (100 mg/day subcutaneously) and canakinumab (150 mg/month subcutaneously) are used with encouraging results, complete remission rate ranging from 83 to 100% with partial remission for most of the remaining cases. IL-1 blockade reduces inflammatory markers, and it is particularly effective on inflammatory, articular, and cutaneous manifestations, but seems not to alter paraprotein concentration in serum, and its efficacy in preventing lymphoproliferative disease progression is uncertain [2, 5, 7–9].

Case report

A 21-year-old woman presented to our outpatient clinic with a 2-year history of recurrent episodes of non-pruritic urticaria and cutaneous angioedema, swelling at proximal interphalangeal joints and wrists, diffuse arthralgias and fever (up to 39 °C), without clear periodicity, nor identified triggering factor, especially in the evening. She had already undergone infectious disease and dermatologic and allergologic evaluation and was previously treated with corticosteroids, antihista- mines, cyclosporine (100 mg/day), and omalizumab without benefit. She had no family history of fever, rheumatic, dermatologic, or autoimmune diseases. When she came to our attention she was in partial remission with 37.5 mg of prednisone daily. She was admitted to our ward, and extensive laboratory testing was performed, revealing elevated CRP (59 mg/L, normal value 0–5 mg/L) and ESR (74 mm/h, 0–20 mm/h) microcytic anemia (hemoglobin 9.5 g/L, mean cellular value 82.0 fl) and neutrophilic leukocytosis (white blood cells 22.9 10⁹/L, neutrophils 21.2 10⁹/L). IgM levels were slightly elevated (2.75 g/L, normal value 0.4–2.3 g/L), while IgA, IgE, and IgG levels were normal. Serum protein electrophoresis revealed an inflammatory pattern, without any monoclonal gammopathy, and urinary Bence-Jones protein was negative. Antinuclear antibodies were positive at 1:80, with a homogenous pattern. Other autoimmunity and oncologic and hematologic screenings, infectious diseases, and bone turnover assessments did not show alterations and are summarized in Table 1. Chest X-ray and abdomen US were performed, without evidence of any pathological finding, especially enlarged spleen or bone lesions. PET-CT showed diffuse homogenous bone marrow uptake and slight splenic uptake. A cutaneous biopsy was also performed, revealing leukocytoclastic neutrophilic infiltration with minimal vasculitic aspects and a minimum amount of dermal edema. No pathological findings were found during cardiologic, ophthalmologist, and otolaryngologist evaluations.

The clinical presentation and the histological findings were highly suggestive for SchS, even if the patients lacked monoclonal gammopathy (confirmed with sensitive immunofixation); thus, we decided to try IL-1 blockade therapy.

We started treatment with anakinra 100 mg subcutaneous daily with total remission of urtica, fever, and arthralgias in 48 h; thus, we decided to confirm SchS diagnosis. Prednisone was tapered and discontinued in 2 months. After 5 months from the beginning of the treatment with anakinra, the patient developed mild neutropenia (N 1600/mmc) and anakinra was switched to 100 mg every other day without relapses, and at the 8 months of treatment, anakinra was further reduced to 3 days a week. After 15 months the patient reported small urticaria lesions on the days off treatment and she switched back to 1 injection any other day with the resolution of the lesions. At the last visit, after 24 months of follow-up, the patient remains asymptomatic. The laboratory tests are normal and without the development of monoclonal gammopathy or remarkable changes in IgM concentrations. Relevant testing trends in time are summarized in Table 2.

Table 1

| Diagnostic tests performed |
|-----------------------------|
| Radio immunoassay test for Immunoglobulin E, angiotensin-converting enzyme, tryptase, C1 inhibitor, complement component 3 and 4, transaminases, γ-glutamyl-transferase, creatine kinase, lactate dehydrogenase, rheumatoid factor, anti-citrullinated protein antibodies, anti-extractable nuclear antigens antibodies, anti-double strand DNA antibodies, cryoglobulins, beta-2 microglobulin, BCR/ABL and Jak2 mutation, infectious disease screening, alkaline phosphatase, and C terminal telopeptide |

Search strategy

We performed a review of the literature available on MEDLINE/Pubmed and Researchgate databases, searched in August 2020, using the following query boxes: ((Schnitzler’s syndrome)AND((without)OR(absence)OR(delayed))AND(−monoclonal)AND(gammopathy)); ((Schnitzler’s syndrome)AND((without)OR(absence)OR(delayed))AND(−paraprotein)). We analyzed the retrieved articles, focusing on case reports of Schnitzler syndrome without monoclonal gammopathy, deleting double reports, and checking their references for further cases. We summarized the relevant features of retrieved cases in Table 3.

Discussion

Despite the lacking of a monoclonal gammopathy, which prevented the fulfillment of diagnostic criteria, our case is typical for SchS in many regards: age of onset, histological findings, and response to IL-1 blockade therapy. However, to our knowledge, this is the first report of SchS without monoclonal gammopathy in Italy. We retrieved only 7 further case
reports of patients diagnosed with SchS without monoclonal gammopathy [10–15].

The average age at presentation of the disease was 51 years old, mostly males (6/8). Six of them had skin biopsies performed, which were all positive for neutrophilic urticaria.

A wide range of other treatments was reported in these patients: prednisone, NSAIDs and thalidomide, interferon γ, azathioprine, anti-TNF, and methotrexate. Coherently with available data for SchS some of these treatments brought only symptomatic relief, mainly on arthralgias, but failed to achieve remission in any patient. Our patient was treated with omalizumab, which proved to be ineffective in treating inflammatory symptoms of Schs. Indeed, SchS is not an IgE-mediated inflammatory condition, as highlighted also by Nham T et al. [16].

Six patients were treated with IL-1 blocking therapies: anakinra 100 mg daily (n = 4) and canakinumab 150 mg every 4 weeks (n = 2). One patient was treated with both drugs. All patients achieved remission. Reported IL-1 blockade therapy adverse events were injection site reaction (n = 3) and transient neutropenia (n = 1). One patient died due to ventricular tachycardia after the beginning of canakinumab treatment, but the patient had pre-existing heart disease.

Follow-up duration was reported for 6 out of 8 patients and varied between 3 and 48 months (average = 18.2 months). Four patients, including the one we described, had slightly

Table 3  Literature review of reported cases of Schnitzler’s Syndrome without monoclonal gammopathy and described case comparison

| Author, yr | Age (yrs) | Sex | Monoclonal gammopathy (quantity) (FU) | Treatment(s) | IL-1 blockade treatment(s) | Outcome (timing) | AEs |
|------------|-----------|-----|--------------------------------------|--------------|----------------------------|------------------|-----|
| Gladue HS, 2014 | 58 M | IgM k (20 months) | CS, MTX, ETN, IFX | Anakinra Canakinumab | Initial response | Severe site injection reaction (anakinra) | Death (ventricular tachycardia) |
|           | 44 F | No (N/A) | Any | Anakinra Canakinumab | Remission | Severe site injection reaction (anakinra) |
| Husak R, 2000 | 57 M | Total IgM elevation (6.5 g/L) (24 months) | Antihistamine, CS, trofosfamide, AZA, colchicine, PEX, IFN-α | No |
| Varella TCN, 2005 | 36 M | Total IgM elevation (3.7 g/L) (N/A) | Thalidomide, antihistamine, NSAIDs, IFN-α | No |
| Urbanski M, 2016 | 62 M | No (14 months) | MTX, AZA, dapsone, ADA, colchicine | Anakinra | Remission (24 h) | No |
| Mulla E, 2015 | 71 M | Total IgM elevation (4.7 g/L) monoclonal IgM k (48 months) | CS, colchicine | Anakinra | Remission (days) | No |
| Ahn MJ, 2018 | 69 M | No (3 months) | ETN, antihistamine, CS, colchicine, CsA, dapsone, MTX | Anakinra | Remission (24 h) | Mild site injection reaction |
| described case | 21 F | Total IgM elevation (2.57 g/L) (24 months) | NSAIDs, CS, CsA, omalizumab | Anakinra | Remission (48 h) | Neutropenia |

yrs. years, CsA cyclosporine, MTX methotrexate, AE adverse events, CS corticosteroids, NSAIDs non steroidal anti-inflammatory drugs, ETN etanercept, ADA adalimumab, AZA azathioprine, PEX plasma exchange, IFX infliximab, IFN-α interferon α, FU follow-up, N/A not available
elevated total IgM (range 2.57–6.5 g/L; average 4.4 g/L) at diagnosis. Two patients developed IgM k chain monoclonal gammopathy after 20 and 48 months from the initial evaluation (average = 34 months). One of them had previously total IgM elevation and was already in treatment with anakinra, while the other started IL-1 blockade after the finding of monoclonal gammopathy [10, 11]. These findings appear consistent with the reported inefficacy of IL-1 blockade in reducing paraprotein concentration in SchS patients [2, 4].

Lastly, several alternative diagnoses must be ruled out before diagnosing SchS, as this condition shares many clinical features with a number of systemic inflammatory diseases. In our case, the age of onset (21 years old), the lack of fever periodicity, and trigger factors were less typical of CAPS or TRAPS. Absent anti-double strand DNA antibodies, normal complement levels, negative ANA, and not detectable cryoglobulins excluded SLE, AAV, and cryoglobulinemia. The urticarial lesions were also more consistent with SchS than AOSD or Sweet’s syndrome. Finally, the absence of Bence Jones protein, PET-CT findings, and the favorable outcome ruled out lymphoma.

Conclusions

Is SchS without monoclonal gammopathy a different entity? Husak et al., back in 2000, suggested that the spectrum of SchS should be broadened to include such entity [14]. Our review of the literature retrieved 8 patients with this diagnosis, which would account for a rough 2–3% of the total known cases, even if SchS is probably underdiagnosed [17].

A very high clinical suspicion and an extensive workout to exclude alternative diagnoses are essential to diagnose SchS without monoclonal gammopathy. In this study we also highlight the resolution of fever and rash in all patients treated with IL-1 blockade, but not in patients on other treatments; therefore, we suggest that a trial with IL-1 blockade could be useful to unveil the diagnosis of SchS in the absence of a detectable monoclonal component, as Gusdorf et al. and by Neel et al. suggested for SchS [2, 7].

Authors’ contributions RB provided the conception of the study, literature search, and interpretation of data, drafting the article, revised it critically for important intellectual content; all authors revised the article critically for important intellectual content and gave final approval of the version to be submitted.

Funding Open access funding provided by Università degli Studi di Verona within the CRUI-CARE Agreement.

Data availability No additional data available.

Compliance with ethical standards Disclosures None.

Ethics approval Written informed consent has been obtained from the patient to access and collect data from the medical record to be used in scientific publications.

Consent to participate Written informed consent has been obtained from the patient to access and collect data from the medical record to be used in scientific publications.

Consent for publication Written informed consent has been obtained from the patient to access and collect data from the medical record to be used in scientific publications.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Schnitzler L (1972) Lésions urticariennes chroniques permanentes (érythème pétaloïde?). J Dermatol Angers
2. Gusdorf L, Lipsker D (2017) Schnitzler Syndrome: a Review. Curr Rheumatol Rep 19:46. https://doi.org/10.1007/s11926-017-0673-5
3. Gusdorf L, Asli B, Barbarot S, Néel A, Masseau A, Puéchal X, Gottenberg J-E, Grateau G, Blanchard-Delaunay C, Rizzi R, Lifermann F, Kyndt X, Aubin F, Bessis D, Boye T, Gayet S, Rongioletti F, Sauleau E, Fermand J-P, Lipsker D (2017) Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients. Allergy 72:177–182. https://doi.org/10.1111/all.13035
4. de Koning HD, Schalkwijk V, Stoffels M, Jongekrijg J, Jacobs JFM, Verwiel E, Koenen HJPM, Preijers F, Holzinger D, Joosten I, van der Meer JWM, Simon A (2015) The role of interleukin-1 beta in the pathophysiology of Schnitzler’s syndrome. Arthritis Res Ther 17:187. https://doi.org/10.1186/s13075-015-0696-0
5. de Koning HD (2014) Schnitzler’s syndrome: lessons from 281 cases. Clin Transl Allergy 4:41. https://doi.org/10.1186/2045-7022-4-41
6. Yan R, Cao W, Liu X, Li F, Shen M (2020) A Chinese case series of Schnitzler syndrome and complete remission in one tocilizumab-treated patient. Clin Rheumatol. https://doi.org/10.1007/s10067-020-05204-2
7. Néel A, Henry B, Barbarot S, Masseau A, Perrin F, Bernier C, Kyndt X, Puechal X, Weiller P-J, Decaux O, Ninet J, Hot A, Aouba A, Astudillo L, Berthelot J-M, Bonnet F, Brisseau J-M, Cador B, Closs-Prophete F, Dejoie T, de Korwin J-D, Dhote R, Fior R, Grosbois B, Hachulla E, Hatron P-Y, Jardel H, Launay D, Lorleac’h A, Pottier P, Moulin G, Serratrice J, Smail A, Hamidou M (2014) Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler’s syndrome: a French multicenter study. Autoimmun Rev 13:1035–1041. https://doi.org/10.1016/j.autrev.2014.08.031
8. Krause K, Bonnekoh H, Ellrich A, Tsiapanakas A, Wagner N, Fischer J, Maurer M (2020) Long-term efficacy of canakinumab in the...
treatment of Schnitzler syndrome. J Allergy Clin Immunol 145:1681–1686.e5. https://doi.org/10.1016/j.jaci.2019.12.909

9. Besada E, Nossent H (2010) Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler’s syndrome: a case report and literature review. Clin Rheumatol 29:567–571. https://doi.org/10.1007/s10067-010-1375-9

10. Mulla E, Neame R (2015) Delayed development of the IgM paraprotein in Schnitzler’s syndrome. Scand J Rheumatol 44:521–522. https://doi.org/10.3109/03009742.2015.1071421

11. Gladue SH (2014) Schnitzler’s syndrome in the absence of a monoclonal gammopathy: a report of two cases. J Clin Cell Immunol 05. https://doi.org/10.4172/2157-9899.1000265

12. Varella TCN, Nishimura MY, Machado MCR, de Moraes-Vasconcelos D, Rivitti EA (2005) Schnitzler’s syndrome without monoclonal gammopathy. Acta Derm Venereol (1):1–1. https://doi.org/10.1080/00015550410026119

13. Ahn MJ, Yu JE, Jeong J, Sim DW, Koh Y-I (2018) A case of Schnitzler’s syndrome without monoclonal gammopathy-associated chronic urticaria treated with anakinra. Yonsei Med J 59:154. https://doi.org/10.3349/ymj.2018.59.1.154

14. Husak R, Nestoris S, Goerd S, Orfanos CE (2000) Severe course of chronic urticaria, arthralgia, fever and elevation of erythrocyte sedimentation rate: Schnitzler’s syndrome without monoclonal gammopathy? Br J Dermatol 142:581. https://doi.org/10.1046/j.1365-2133.2000.03379.x

15. Urbanski M, Holfeld K, Milne A, Abbas M (2016) Schnitzler syndrome without a monoclonal gammopathy: a case report. J Cutan Med Surg 20:575–578. https://doi.org/10.1177/1203475416657999

16. Nham T, Saleh C, Chu D, Vakaljan SL, Ohayon JA, Siegal DM (2019) Refractory urticaria and the importance of diagnosing Schnitzler’s syndrome. BMJ Case Rep 12. https://doi.org/10.1136/bcr-2018-228546

17. Jain T, Offord CP, Kyle RA, Dingli D (2013) Schnitzler syndrome: an under-diagnosed clinical entity. Haematologica 98:1581–1585. https://doi.org/10.3324/haematol.2013.084830

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.